Amgen Inc (AMGN) - Stock Report

Investigación informativa — no es asesoramiento de inversión.Aviso legal completo

Investigación informativa — no es asesoramiento de inversión. Generado en parte por IA y puede contener errores; no es una recomendación personalizada, solicitud u oferta. ReasyPort no es una empresa de inversión autorizada ni regulada. Los datos de mercado pueden estar retrasados o ser inexactos. El capital está en riesgo y los rendimientos pasados no garantizan resultados futuros — investigue por su cuenta y consulte a un asesor autorizado.

Aviso legal completo
AMGN

Amgen Inc

ReasyPort View: Cautious Watchlist — Portfolio Replacement Proof Required

Summary

Amgen Inc. traded at $350.53 at the 15 June 2026 close, versus a selected fair value of $272.05. The price is about 29% above the selected case, while the upside marker of $357.14 is only about 2% above the market price and the downside marker of $230.25 is about 34% below it. That is a valuation-discipline conclusion, not a business-quality objection: Amgen remains a large branded-therapy cash generator, but the current price already prices in a belief that the replacement cycle can offset Prolia, XGEVA, Enbrel and Otezla pressure without a material cash-conversion reset. The key macro issue is not drug-price pressure in isolation, but whether biosimilar, IRA and payer pressure reduce mature-product profit density faster than Repatha, rare disease, oncology and MariTide can rebuild normalized EBITDA and free cash flow coverage.

Latest Proof Snapshot

The latest evidence is mixed in exactly the way a biopharma transition story should be tested. In Q1 2026, revenue rose 6% to $8.6 bn and product sales grew 4%, with 9% volume growth partly offset by 2% lower net selling price and lower inventory levels; FY2026 guidance calls for revenue of $37.1 bn to $38.5 bn, reported diluted EPS of $15.62 to $17.10, adjusted diluted EPS of $21.70 to $23.10, capex of about $2.6 bn, and buybacks not to exceed $3.0 bn. Reported diluted EPS was $3.34, adjusted diluted EPS was $5.15, reported operating margin improved to 32.4%, and adjusted operating margin slipped to 45.3%. The replacement bridge is visible but incomplete: Repatha rose 34%, EVENITY 27%, TEPEZZA 29%, BLINCYTO 12%, and IMDELLTRA more than tripled, while Prolia fell 34%, XGEVA fell 27%, and Enbrel fell 37%. Q1 company-reported free cash flow was $1.5 bn after $0.7 bn of capex, covering $1.4 bn of dividends with only about $0.1 bn of excess for the quarter and no buybacks; cash was $12.0 bn against $57.3 bn of debt.

Business Overview

What The Company Actually Does

Amgen discovers, develops, manufactures and commercializes human therapeutics. It reports one operating segment, but economically it is a portfolio of branded therapies, led by biologics and including small-molecule products such as Otezla. The company sells through a concentrated pharmaceutical distribution channel, with McKesson, Cencora and Cardinal Health representing 77% of 2025 worldwide gross revenues.

How The Business Is Organized

The value stack is not just holding drug rights. Amgen combines research, clinical development, biologics manufacturing, regulatory execution, payer access and lifecycle management. That stack supports high adjusted margins when mature therapies are protected, but it also creates a permanent replacement requirement because biologics face biosimilars, small molecules face generics, and U.S. pricing pressure can reduce retained economics even when volumes grow.

What Management Appears To Be Prioritizing

Management is trying to keep the cash engine broad enough to absorb a product cliff. The priorities are Repatha expansion, Horizon rare-disease integration, oncology launches such as IMDELLTRA, TEZSPIRE growth, and MariTide. These assets must do more than add revenue; they must replace high-margin mature-product profit while Amgen still funds R&D, dividends, debt service and manufacturing investment.

🔒

Inicia sesión para leer el informe completo

Crea una cuenta gratuita para desbloquear el resto del informe y acceder a toda nuestra biblioteca.